APA (7th ed.) Citation

Bozorgmehr, F., Chung, I., Christopoulos, P., Krisam, J., Schneider, M., Brückner, L. M., . . . Rieken, S. (2020). Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: Study protocol of the TRADE-hypo trial. BMC cancer, 20, . https://doi.org/10.1186/s12885-020-07264-8

Chicago Style (17th ed.) Citation

Bozorgmehr, Farastuk, Inn Chung, Petros Christopoulos, Johannes Krisam, Marc Schneider, Lena Marie Brückner, Daniel Wilhelm Müller, Michael Thomas, and Stefan Rieken. "Thoracic Radiotherapy Plus Durvalumab in Elderly And/or Frail NSCLC Stage III Patients Unfit for Chemotherapy - Employing Optimized (hypofractionated) Radiotherapy to Foster Durvalumab Efficacy: Study Protocol of the TRADE-hypo Trial." BMC Cancer 20 (2020). https://doi.org/10.1186/s12885-020-07264-8.

MLA (9th ed.) Citation

Bozorgmehr, Farastuk, et al. "Thoracic Radiotherapy Plus Durvalumab in Elderly And/or Frail NSCLC Stage III Patients Unfit for Chemotherapy - Employing Optimized (hypofractionated) Radiotherapy to Foster Durvalumab Efficacy: Study Protocol of the TRADE-hypo Trial." BMC Cancer, vol. 20, 2020, https://doi.org/10.1186/s12885-020-07264-8.